Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niclosamide SCHEMBL27365268 | 1.00 | KMT2A (1.00) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL29363878 | 1.00 | KMT2A (1.00) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL28313524 | 1.00 | KMT2A (1.00) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL67182 | 1.00 | KMT2A (1.00) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL2061202 | 0.99 | KMT2A (0.97) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL27937315 | 0.99 | KMT2A (0.97) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL31098821 | 0.99 | KMT2A (0.97) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL16686086 | 0.97 | KMT2A (0.95) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL1526777 | 0.97 | KMT2A (0.95) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL23753582 | 0.94 | LMNA (0.89) | KMT2AMEN1MAPTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414637-A1 | NICLOSAMIDE NASAL AND THROAT SPRAY | NEEDHAM MATERIAL SCIENCE LLC | 2023-12-28 | — | — | US | disclosed |
| US-10980756-B1 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10799468-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200315996-A1 | Treatment of Endometriosis and Niclosamide Derivatives | BOARD OF TRUSTEES, SOUTHERN ILLINOIS UNIVERSITY (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2017-03-02 | — | — | US | disclosed |
| WO-2004006906-A2 | METHODS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200315996-A1 | Treatment of Endometriosis and Niclosamide Derivatives | STAT3, ESR2, STAT1 | KMT2A 437/4885MEN1 4135/4885MAPT 4420/4885 |
| US-10799468-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | KMT2A 3619/4885MEN1 3451/4885MAPT 969/4885 |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KMT2A 3619/4885MEN1 3451/4885MAPT 969/4885 |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KMT2A 3619/4885MEN1 3451/4885MAPT 969/4885 |
| US-10980756-B1 | Methods of treatment | ACE2, ACE, SI | KMT2A 2952/4885MEN1 1488/4885MAPT 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.